Search

Displaying results 3301 - 3310 of 5263 in total
  1. Drug

    Zenarestat

    go.drugbank.com/drugs/DB02132
    Experimental

  2. Drug

    Iobenguane sulfate I-123

    go.drugbank.com/drugs/DB09546
    Approved

    Iobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

  3. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    [L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]

  4. Drug

    OSI-7836

    go.drugbank.com/drugs/DB05837
    Experimental

    This drug shows no unexpected toxicities; those observed appeared to be similar to other nucleoside agents.

  5. Drug

    ALTU-135

    go.drugbank.com/drugs/DB05330
    Investigational

    ALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA). … ALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase

  6. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    [L50326] It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.

  7. Drug

    MK-4721

    go.drugbank.com/drugs/DB05933
    Investigational

    MK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients

  8. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    This approval was based on positive results demonstrated in the 35-week interim analysis from the Phase 3 NEURO-TTRansform study, where a consistent improvement in the Neuropathy Impairment Score +7 (mNIS … [A262975] Hereditary transthyretin-mediated amyloidosis is caused primarily by pathogenic variants of the TTR gene, leading to the formation and thus accumulation of insoluble and misfolded amyloid in

  9. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    [L42325] Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. … Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.[A36741]

  10. Drug

    Guanadrel

    go.drugbank.com/drugs/DB00226
    Approved

    Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.